| Title |
Safety of repeated transplantations of neurotrophic factors‐secreting human mesenchymal stromal stem cells
|
|---|---|
| Published in |
Clinical and Translational Medicine, July 2014
|
| DOI | 10.1186/2001-1326-3-21 |
| Pubmed ID | |
| Authors |
Yael Gothelf, Natalie Abramov, Adrian Harel, Daniel Offen |
| Abstract |
Therapies based on mesenchymal stem cells (MSC) have been shown to have potential benefit in several clinical studies. We have shown that, using a medium-based approach, MSC can be induced to secrete elevated levels of neurotropic factors, which have been shown to have protective effects in animal models of neurodegenerative diseases. These cells, designated MSC-NTF cells (Neurotrophic factor-secreting MSC, also known as NurOwn™) derived from the patient's own bone marrow, have been recently used for Phase I/II and Phase IIa clinical studies in patients with Amyotrophic Lateral Sclerosis (ALS). In these studies, ALS patients were subjected to a single administration of autologous MSC-NTF cells. The data from these studies indicate that the single administration of MSC-NTF cells is safe and well tolerated. In a recently published case report, it was shown that repeated MSC-NTF injections in an ALS patient treated on a compassionate basis were safe and well tolerated [Muscle Nerve 49:455-457, 2014]. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Scientists | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Korea, Republic of | 1 | 2% |
| United States | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 47 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 20% |
| Student > Master | 9 | 18% |
| Researcher | 8 | 16% |
| Other | 5 | 10% |
| Student > Bachelor | 3 | 6% |
| Other | 9 | 18% |
| Unknown | 7 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 24% |
| Agricultural and Biological Sciences | 11 | 22% |
| Biochemistry, Genetics and Molecular Biology | 7 | 14% |
| Neuroscience | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 10 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2019.
All research outputs
#6,443,738
of 25,374,647 outputs
Outputs from Clinical and Translational Medicine
#246
of 1,060 outputs
Outputs of similar age
#56,513
of 240,568 outputs
Outputs of similar age from Clinical and Translational Medicine
#3
of 9 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,060 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,568 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.